The revolutionary Spanish pharmaceutical company has recieved 11 new authorizations of Yondelis in 8 countries: Bahrain, Belarus, Canada, Egypt, El Salvador, Indonesa, Qatar and Honduras. Yondelis is currenltly approved in 70 countries.
Zeltia submitted to the CNMV (the Spanish SEC), through its subsidiary Pharma Mar, the 11 new authorizations for the commercialization of Yondelis in 8 countries.
The company notes that "four of these authorizations are for the treatment of recurrent ovarian cancer in combination with Caelyx and the remaining seven for the treatment of soft tissue sarcoma".
